

**KDL BIOTECH LIMITED**  
**Registered Office & Works : Village Savroli, Tal. Khalapur, Dist. Raigad, Maharashtra - 410 202.**

Part I

**Statement of Standalone Unaudited Results for the Quarter Ended 30/09/2012**

(Rupees in lakhs)

| Particulars                                                                                                   | 3 Months ended<br>(30/09/2012) | Preceding 3<br>Months ended<br>(30/06/2012) | Corresponding<br>3 Months<br>ended in the<br>previous year<br>(30/09/2011) | 6 Months<br>ended in the<br>current year<br>(30/09/2012) | 6 Months<br>ended in the<br>previous year<br>(30/09/2011) | Previous year<br>ended<br>(31/03/2012) |
|---------------------------------------------------------------------------------------------------------------|--------------------------------|---------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------|
|                                                                                                               | Unaudited                      | Unaudited                                   | Unaudited                                                                  | Unaudited                                                | Unaudited                                                 | Audited                                |
| <b>1. Income from Operations</b>                                                                              |                                |                                             |                                                                            |                                                          |                                                           |                                        |
| (a) Net Sales/Income from Operations<br>(Net of excise duty)                                                  | 167.14                         | 168.41                                      | 171.52                                                                     | 335.54                                                   | 277.19                                                    | 850.22                                 |
| (b) Other Operating Income<br>(Job Work Charges Received)                                                     | 490.13                         | 315.93                                      | 678.40                                                                     | 806.06                                                   | 1078.43                                                   | 1,796.35                               |
| <b>Total income from Operations (net)</b>                                                                     | <b>657.26</b>                  | <b>484.34</b>                               | <b>849.92</b>                                                              | <b>1,141.60</b>                                          | <b>1,355.62</b>                                           | <b>2,646.57</b>                        |
| <b>2. Expenses</b>                                                                                            |                                |                                             |                                                                            |                                                          |                                                           |                                        |
| a. Cost of Materials consumed                                                                                 | 55.84                          | 4.48                                        | 20.30                                                                      | 60.33                                                    | 23.88                                                     | 46.64                                  |
| b. Purchase of stock-in-trade                                                                                 | 106.89                         | 111.44                                      | 116.95                                                                     | 218.34                                                   | 199.14                                                    | 423.51                                 |
| c. Changes in inventories of finished goods, work-in-progress and stock-in-trade                              | 0.00                           | 0.00                                        | 0.00                                                                       | 0.00                                                     | 0.00                                                      | 0.00                                   |
| d. Employee benefits expenses                                                                                 | 262.82                         | 239.94                                      | 244.40                                                                     | 502.75                                                   | 484.55                                                    | 964.94                                 |
| e. Depreciation, amortisation and impairment                                                                  | 174.18                         | 171.96                                      | 248.29                                                                     | 346.14                                                   | 494.60                                                    | 913.29                                 |
| f. Other expenses                                                                                             | 272.57                         | 268.96                                      | 414.17                                                                     | 541.53                                                   | 732.89                                                    | 1,418.12                               |
| <b>Total Expenses</b>                                                                                         | <b>872.30</b>                  | <b>796.78</b>                               | <b>1,044.11</b>                                                            | <b>1,669.09</b>                                          | <b>1,935.07</b>                                           | <b>3,766.51</b>                        |
| <b>3. Profit / (Loss) from Operations before other income, finance costs and exceptional items (1-2)</b>      | <b>(215.04)</b>                | <b>(312.44)</b>                             | <b>(194.19)</b>                                                            | <b>(527.48)</b>                                          | <b>(579.44)</b>                                           | <b>(1,119.94)</b>                      |
| <b>4. Other Income</b>                                                                                        | <b>7.96</b>                    | <b>8.23</b>                                 | <b>8.39</b>                                                                | <b>16.20</b>                                             | <b>16.44</b>                                              | <b>75.84</b>                           |
| <b>5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>           | <b>(207.08)</b>                | <b>(304.20)</b>                             | <b>(185.80)</b>                                                            | <b>(511.28)</b>                                          | <b>(563.00)</b>                                           | <b>(1,044.10)</b>                      |
| <b>6. Finance Costs</b>                                                                                       | <b>172.51</b>                  | <b>168.66</b>                               | <b>166.10</b>                                                              | <b>341.16</b>                                            | <b>332.67</b>                                             | <b>677.15</b>                          |
| <b>7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>     | <b>(379.59)</b>                | <b>(472.86)</b>                             | <b>(351.90)</b>                                                            | <b>(852.45)</b>                                          | <b>(895.67)</b>                                           | <b>(1,721.24)</b>                      |
| <b>8. Exceptional Items</b>                                                                                   | <b>0.00</b>                    | <b>0.00</b>                                 | <b>0.00</b>                                                                | <b>0.00</b>                                              | <b>0.00</b>                                               | <b>0.00</b>                            |
| <b>9. Profit / (Loss) from ordinary activities before tax (7+8)</b>                                           | <b>(379.59)</b>                | <b>(472.86)</b>                             | <b>(351.90)</b>                                                            | <b>(852.45)</b>                                          | <b>(895.67)</b>                                           | <b>(1,721.24)</b>                      |
| <b>10. Tax expense</b>                                                                                        | <b>0.00</b>                    | <b>0.00</b>                                 | <b>0.00</b>                                                                | <b>0.00</b>                                              | <b>0.00</b>                                               | <b>0.00</b>                            |
| <b>11. Net Profit / (Loss) from ordinary activities after tax (9-10)</b>                                      | <b>(379.59)</b>                | <b>(472.86)</b>                             | <b>(351.90)</b>                                                            | <b>(852.45)</b>                                          | <b>(895.67)</b>                                           | <b>(1,721.24)</b>                      |
| <b>12. Extraordinary Items</b>                                                                                | <b>0.00</b>                    | <b>0.00</b>                                 | <b>0.00</b>                                                                | <b>0.00</b>                                              | <b>0.00</b>                                               | <b>0.00</b>                            |
| <b>13. Net Profit / (Loss) for the period (11+12)</b>                                                         | <b>(379.59)</b>                | <b>(472.86)</b>                             | <b>(351.90)</b>                                                            | <b>(852.45)</b>                                          | <b>(895.67)</b>                                           | <b>(1,721.24)</b>                      |
| <b>14. Paid-up equity share capital Equity Shares of Rs. 10/- each</b>                                        | <b>2,403.52</b>                | <b>2,403.52</b>                             | <b>2,403.52</b>                                                            | <b>2,403.52</b>                                          | <b>2,403.52</b>                                           | <b>2,403.52</b>                        |
| <b>15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>            | <b>0.00</b>                    | <b>0.00</b>                                 | <b>0.00</b>                                                                | <b>0.00</b>                                              | <b>0.00</b>                                               | <b>(8,320.84)</b>                      |
| <b>16. (i) Earnings Per Share (before extraordinary items) (Face Value of Rs. 10/- each) (not annualised)</b> |                                |                                             |                                                                            |                                                          |                                                           |                                        |
| (a) Basic                                                                                                     | (1.58)                         | (1.97)                                      | (1.46)                                                                     | (3.55)                                                   | (3.73)                                                    | (7.16)                                 |
| (b) Diluted                                                                                                   | (1.58)                         | (1.97)                                      | (1.46)                                                                     | (3.55)                                                   | (3.73)                                                    | (7.16)                                 |
| <b>16. (ii) Earnings Per Share (after extraordinary items) (Face Value of Rs. 10/- each) (not annualised)</b> |                                |                                             |                                                                            |                                                          |                                                           |                                        |
| (a) Basic                                                                                                     | (1.58)                         | (1.97)                                      | (1.46)                                                                     | (3.55)                                                   | (3.73)                                                    | (7.16)                                 |
| (b) Diluted                                                                                                   | (1.58)                         | (1.97)                                      | (1.46)                                                                     | (3.55)                                                   | (3.73)                                                    | (7.16)                                 |

9/11  
 2012

**KDL BIOTECH LIMITED**

**Registered Office & Works : Village Savroli, Tal. : Khalapur, Khopoli, Dist. : Raigad, Maharashtra - 410 202.**  
**Tel. : 02192 - 274 026 to 274 029 • Fax : 02192 - 274 031**



Biotech

Part II

Select Information for the Quarter Ended 30/09/2012

|                                                                                              | 3 Months ended<br>(30/09/2012) | Preceding 3 Months ended<br>(30/06/2012) | Corresponding 3 Months ended in the previous year<br>(30/09/2011) | 6 Months ended in the current year<br>(30/09/2012) | 6 Months ended in the previous year<br>(30/09/2011) | Previous year ended<br>(31/03/2012) |
|----------------------------------------------------------------------------------------------|--------------------------------|------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|-------------------------------------|
|                                                                                              | Unaudited                      | Unaudited                                | Unaudited                                                         | Unaudited                                          | Unaudited                                           | Audited                             |
| <b>A. PARTICULARS OF SHAREHOLDING</b>                                                        |                                |                                          |                                                                   |                                                    |                                                     |                                     |
| <b>1. Public shareholding</b>                                                                |                                |                                          |                                                                   |                                                    |                                                     |                                     |
| - Number of shares                                                                           | 7,485,241                      | 7,485,241                                | 7,485,241                                                         | 7,485,241                                          | 7,485,241                                           | 7,485,241                           |
| - Percentage of shareholding                                                                 | 31.14%                         | 31.14%                                   | 31.14%                                                            | 31.14%                                             | 31.14%                                              | 31.14%                              |
| <b>2. Promoters and Promoter Group Shareholding</b>                                          |                                |                                          |                                                                   |                                                    |                                                     |                                     |
| <b>a) Pledged / Encumbered</b>                                                               |                                |                                          |                                                                   |                                                    |                                                     |                                     |
| - Number of shares                                                                           | -                              | -                                        | -                                                                 | -                                                  | -                                                   | -                                   |
| - Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) | -                              | -                                        | -                                                                 | -                                                  | -                                                   | -                                   |
| - Percentage of shares (as a % of the total share capital of the company)                    | -                              | -                                        | -                                                                 | -                                                  | -                                                   | -                                   |
| <b>b) Non - Encumbered</b>                                                                   |                                |                                          |                                                                   |                                                    |                                                     |                                     |
| - Number of shares                                                                           | 16,549,910                     | 16,549,910                               | 16,549,910                                                        | 16,549,910                                         | 16,549,910                                          | 16,549,910                          |
| - Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) | 100%                           | 100%                                     | 100%                                                              | 100%                                               | 100%                                                | 100%                                |
| - Percentage of shares (as a % of the total share capital of the company)                    | 68.86%                         | 68.86%                                   | 68.86%                                                            | 68.86%                                             | 68.86%                                              | 68.86%                              |
| <b>B. INVESTOR COMPLAINTS</b>                                                                |                                |                                          |                                                                   |                                                    |                                                     |                                     |
| Pending at the beginning of the quarter                                                      | 0                              |                                          |                                                                   |                                                    |                                                     |                                     |
| Received during the quarter                                                                  | 0                              |                                          |                                                                   |                                                    |                                                     |                                     |
| Disposed of during the quarter                                                               | 0                              |                                          |                                                                   |                                                    |                                                     |                                     |
| Remaining unresolved at the end of the quarter                                               | 0                              |                                          |                                                                   |                                                    |                                                     |                                     |

**NOTES**

- 1) The above un-audited results have been reviewed by the Audit Committee and approved and taken on record by the Board of Directors in their meeting held on November 12, 2012.
- 2) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
- 3) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
- 4) During the quarter no complaint/reference was received from investors and there were no Investor complaints/references pending at the beginning as well as at the end of the quarter.
- 5) The Company had submitted revised One Time Settlement (OTS) proposal on March 01, 2012 to the bankers which is pending.
- 6) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.
- 7) The Company has made reference with BIFR on June 06, 2011. The case is registered with the BIFR for determination of status of company's sickness and at the hearing held on 16-10-2012, the BIFR has reserved its order.
- 8) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. DRT has stayed the matter in view of the reference made by the Company to BIFR.
- 9) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The auditors have qualified their limited review report for this matter. The Company's management believes that pending finality of the reference filed with BIFR as well as OTS proposal, no penal interest and additional interest needs to be accrued on the loans at this point of time.

For and on behalf of the Board of Directors

  
 Dr. Rajesh Agrawal  
 (Director- Technical)

 Place : Mumbai  
 Dated : November 12, 2012

KDL BIOTECH LIMITED

 Registered Office & Works : Village Savroli, Tal. : Khalapur, Khopoli, Dist. : Raigad, Maharashtra - 410 202  
 Tel. : 02192 - 274 026 to 274 029 • Fax : 02192 - 274 031

**KDL - Biotech Limited**

**Statement of Assets and Liabilities**

(Rupees in lakhs)

| Sr. No.   | Particulars                       | As at 30th Sept 2012 |                 | As at 31st March 2012 |                 |
|-----------|-----------------------------------|----------------------|-----------------|-----------------------|-----------------|
| <b>I</b>  | <b>EQUITY AND LIABILITIES</b>     |                      |                 |                       |                 |
| (1)       | <b>Shareholder's Funds</b>        |                      |                 |                       |                 |
|           | (a) Share capital                 | 2403.52              |                 | 2,403.52              |                 |
|           | (b) Reserves and surplus          | (9,173.28)           | (6,769.76)      | (8,320.84)            | (5,917.32)      |
| (2)       | <b>Non-current liabilities</b>    |                      |                 |                       |                 |
|           | (a) Long-term borrowings          |                      | 3.91            |                       | 4.42            |
|           | (a) Long-term Provisions          |                      | 266.05          |                       | 261.40          |
| (3)       | <b>Current liabilities</b>        |                      |                 |                       |                 |
|           | (a) Short-term borrowings         | 5,105.51             |                 | 5,137.77              |                 |
|           | (b) Trade payables                | 514.65               |                 | 548.32                |                 |
|           | (c) Other current liabilities     | 6,123.62             |                 | 5,585.33              |                 |
|           | (d) Short-term provisions         | 49.94                | 11,793.72       | 49.94                 | 11,321.36       |
|           | <b>TOTAL</b>                      |                      | <b>5,293.92</b> |                       | <b>5,669.86</b> |
| <b>II</b> | <b>ASSETS</b>                     |                      |                 |                       |                 |
|           | <b>Non-current assets</b>         |                      |                 |                       |                 |
| (1)       | (a) Fixed assets                  |                      |                 |                       |                 |
|           | (i) Tangible assets               | 4,470.68             |                 | 4,805.99              |                 |
|           | (ii) Intangible assets            | -                    |                 | -                     |                 |
|           | (ii) Capital work-in-progress     | -                    | 4,470.68        | -                     | 4,805.99        |
|           | (b) Non-current investments       |                      | 0.72            |                       | 0.72            |
|           | (c) Long-term Loans and advances  |                      | 43.61           |                       | 36.74           |
|           | (d) Other Non-Current Assets      |                      | 136.99          |                       | 136.99          |
| (2)       | <b>Current assets</b>             |                      |                 |                       |                 |
|           | (a) Inventories                   | 210.77               |                 | 251.28                |                 |
|           | (b) Trade receivables             | 4.29                 |                 | 1.61                  |                 |
|           | (c) Cash and cash equivalents     | 45.53                |                 | 53.67                 |                 |
|           | (d) Short-term loans and advances | 20.91                |                 | 23.42                 |                 |
|           | (e) Other current assets          | 360.42               | 641.92          | 359.44                | 689.42          |
|           | <b>TOTAL</b>                      |                      | <b>5,293.92</b> |                       | <b>5,669.86</b> |

**For and on behalf of the Board of Directors**



**Dr. Rajesh Agrawal**  
(Director- Technical)

**Place : Mumbai**

**Dated : November 12, 2012**



**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khalapur, Khopoli, Dist. : Raigad, Maharashtra - 410 202.  
Tel. : 02192 - 274 026 to 274 029 • Fax : 02192 - 274 031